Literature DB >> 7532196

Relative amounts of keratin 17 are higher than those of keratin 16 in hair-follicle-derived tumors in comparison with nonfollicular epithelial skin tumors.

K Yoshikawa1, Y Katagata, S Kondo.   

Abstract

Specimens of trichilemmal cyst, malignant trichilemmoma, keratoacanthoma, and epidermal cyst were examined to characterize keratin peptides in hair-follicle-derived tumors. Keratins were extracted from the specimens and analyzed by two-dimensional gel electrophoresis and densitometry; the results were then compared with those for normal epidermis, the outer root sheath of hair follicles, psoriatic epidermis, and various nonfollicular cutaneous epithelial tumors. The specific nonfollicular tumors examined were squamous cell carcinoma, Bowen disease, actinic keratosis, eccrine porocarcinoma, and sebaceous carcinoma. Immunohistochemistry also was performed with a few anti-keratin monoclonal antibodies. As a general rule, K6 and K16 were expressed in hyperproliferative conditions, such as epidermal tumors, and K17 was coexpressed in the same lesions. The ratio of K16 to K17 in many epithelial skin tumors has been unclear until now. K17 content exceeded K16 content in most follicular tumors, whereas in almost all the nonfollicular tumors and the psoriatic epidermis, K17 levels were less than or about equal to K16 levels. There was a significant difference in the ratio of K16 to K17 between follicular and nonfollicular skin tumors. These results indicate that alterations in the content of these keratins may be associated with follicular differentiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532196     DOI: 10.1111/1523-1747.ep12665888

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  6 in total

1.  Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened.

Authors:  Tracy Tang; Jean Y Tang; Dongwei Li; Mike Reich; Christopher A Callahan; Ling Fu; Robert L Yauch; Frank Wang; Karen Kotkow; Kris S Chang; Elana Shpall; Angela Wu; Lee L Rubin; James C Marsters; Ervin H Epstein; Ivor Caro; Frederic J de Sauvage
Journal:  Clin Cancer Res       Date:  2011-05-10       Impact factor: 12.531

2.  Treatment of keratoacanthoma with 5% imiquimod cream and review of the previous report.

Authors:  Hye Chan Jeon; Mira Choi; Seung Hwan Paik; Chang Ho Ahn; Hyun Sun Park; Kwang Hyun Cho
Journal:  Ann Dermatol       Date:  2011-08-06       Impact factor: 1.444

3.  Diagnostic utility of cytokeratin 17 immunostaining in morpheaform basal cell carcinoma and for facilitating the detection of tumor cells at the surgical margins.

Authors:  Heidi Anderson-Dockter; Todd Clark; Satori Iwamoto; Ming Lu; David Fiore; Jane K Falanga; Vincent Falanga
Journal:  Dermatol Surg       Date:  2012-06-12       Impact factor: 3.398

4.  Computer Image Analysis Reveals C-Myc as a Potential Biomarker for Discriminating between Keratoacanthoma and Cutaneous Squamous Cell Carcinoma.

Authors:  Xinyun Fan; Xueli Niu; Ze Wu; Lu Yao; Shirui Chen; Wenyu Wan; Bo Huang; Rui-Qun Qi; Tao Zhang
Journal:  Biomed Res Int       Date:  2022-08-23       Impact factor: 3.246

5.  Onset of re-epithelialization after skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes: defining a potential role for keratin 16.

Authors:  R D Paladini; K Takahashi; N S Bravo; P A Coulombe
Journal:  J Cell Biol       Date:  1996-02       Impact factor: 10.539

6.  Non‑invasive proteome‑wide quantification of skin barrier‑related proteins using label‑free LC‑MS/MS analysis.

Authors:  Mengting Liu; Jing Zhang; Yaochi Wang; Cong Xin; Jie Ma; Shuangjun Xu; Xiaomeng Wang; Jinping Gao; Xuejun Zhang; Sen Yang
Journal:  Mol Med Rep       Date:  2020-03-11       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.